Financial Advocates Investment Management’s Decoy Therapeutics DCOY Stock Holding History

Financial Advocates Investment Management’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	-$2K	–	825
2022 Q2	–	Hold	0	–	–	–	684
2022 Q1	–	Hold	0	–	–	–	728
2021 Q4	–	Hold	0	–	-$12K	–	810
2021 Q3	–	Hold	0	–	–	–	739
2021 Q2	–	Hold	0	–	–	–	731
2021 Q1	–	Hold	0	–	–	–	744
2020 Q4	–	Hold	0	–	–	–	714
2020 Q3	–	Hold	0	–	–	–	625
2020 Q2	–	Hold	0	–	–	–	603
2020 Q1	–	Hold	0	–	–	–	475
2019 Q4	–	Sell	-1	Closed	-$160K	–	505
2019 Q3	$119K	Buy	+1	New	+$341K	0.01%	473

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

LNWWM

Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM

Financial Advocates Investment Management's DCOY Position: Q3 2022 in Review

Financial Advocates Investment Management held its Decoy Therapeutics (DCOY) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #825.

Financial Advocates Investment Management first reported a position in DCOY in Q3 2019 and has held it in 1 quarter since. The position peaked at $119K in Q3 2019. 16 funds tracked by Wall St. Rank hold DCOY as of Q3 2022.

Financial Advocates Investment Management held 0 shares of Decoy Therapeutics worth $0 as of Q3 2022.
Financial Advocates Investment Management left its Decoy Therapeutics share count unchanged in Q3 2022.
Decoy Therapeutics made up ﹤0.01% of Financial Advocates Investment Management's portfolio in Q3 2022, its #825 holding.
Financial Advocates Investment Management first reported a position in Decoy Therapeutics in Q3 2019 and has held it in 1 quarter since.
Financial Advocates Investment Management's Decoy Therapeutics position peaked at $119K in Q3 2019.
16 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2022.

Based on Financial Advocates Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.